Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study.
Dimitrakopoulos FI, Mountzios G, Christopoulos P, Papastergiou T, Elshiaty M, Daniello L, Zervas E, Agelaki S, Samantas E, Nikolaidi A, Athanasiadis I, Baka S, Syrigos K, Christopoulou A, Lianos E, Samitas K, Tsoukalas N, Perdikouri EI, Oikonomopoulos G, Kottorou A, Kalofonou F, Makatsoris T, Koutras A, Megalooikonomou V, Kalofonos H. Dimitrakopoulos FI, et al. Ther Adv Med Oncol. 2022 Sep 8;14:17588359221122728. doi: 10.1177/17588359221122728. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36105886 Free PMC article.
PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors.
Dimitrakopoulos FI, Nikolakopoulos A, Kottorou A, Kalofonou F, Liolis E, Frantzi T, Pyrousis I, Koutras A, Makatsoris T, Kalofonos H. Dimitrakopoulos FI, et al. Cancers (Basel). 2020 May 16;12(5):1257. doi: 10.3390/cancers12051257. Cancers (Basel). 2020. PMID: 32429368 Free PMC article.
NF-κB2 and RELB offer prognostic information in colorectal cancer and NFKB2 rs7897947 represents a genetic risk factor for disease development.
Antonacopoulou A, Kottorou AE, Dimitrakopoulos FI, Marousi S, Kalofonou F, Koutras A, Makatsoris T, Tzelepi V, Kalofonos HP. Antonacopoulou A, et al. Among authors: dimitrakopoulos fi. Transl Oncol. 2021 Jan;14(1):100912. doi: 10.1016/j.tranon.2020.100912. Epub 2020 Oct 16. Transl Oncol. 2021. PMID: 33074124 Free PMC article.
Radiotherapy and Renal Cell Carcinoma: A Continuing Saga.
Spyropoulou D, Tsiganos P, Dimitrakopoulos FI, Tolia M, Koutras A, Velissaris D, Lagadinou M, Papathanasiou N, Gkantaifi A, Kalofonos H, Kardamakis D. Spyropoulou D, et al. Among authors: dimitrakopoulos fi. In Vivo. 2021 May-Jun;35(3):1365-1377. doi: 10.21873/invivo.12389. Epub 2021 Apr 28. In Vivo. 2021. PMID: 33910814 Free PMC article. Review.
Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens.
Kourea HP, Dimitrakopoulos FI, Koliou GA, Batistatou A, Papadopoulou K, Bobos M, Asimaki-Vlachopoulou A, Chrisafi S, Pavlakis K, Chatzopoulos K, Galani E, Pentheroudakis G, Pectasides D, Bafaloukos D, Res E, Papakostas P, Koutras A, Kotoula V, Fountzilas G. Kourea HP, et al. Among authors: dimitrakopoulos fi. Cancer Res Treat. 2022 Oct;54(4):1053-1064. doi: 10.4143/crt.2021.748. Epub 2021 Nov 17. Cancer Res Treat. 2022. PMID: 34793664 Free PMC article.
41 results